{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:45:34Z","timestamp":1787010334189,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peptide receptor radioligand therapy (PRRT) was Food and Drug Administration approved in 2018 for the treatment of unresectable somatostatin receptor\u2013positive gastroenteropancreatic neuroendocrine tumors (NETs) and provides an important option for patients with advanced disease. A known adverse effect of this treatment is hematologic toxicity, although usually transient. We present 3 patients with metastatic gastroenteropancreatic NETs treated with PRRT who were evaluated for severe persistent thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Three patients who commenced therapy with PRRT were known to proceed to a bone marrow (BM) biopsy for persistent severe thrombocytopenia and were included in this study. These patients were identified retrospectively and evaluated for their tumor properties, including immunohistochemical markers, treatment modalities, and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All 3 patients had metastatic NETs that progressed on prior lines of therapy and were treated with 1 to 4 doses of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTATATE 7.4 GBq (200 mCi) before developing grade 3 (25,000 to 50,000\/\u03bcL) refractory thrombocytopenia. All patients had concurrent bone metastases, and 2 of the 3 had baseline grade 1 thrombocytopenia. In all 3 cases, BM biopsy documented widespread tumor infiltration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Severe refractory thrombocytopenia after PRRT is rare and may result from numerous known causes, including radiation-induced myelotoxicity, myelodysplastic syndrome, and tumor BM infiltration. We present 3 cases of thrombocytopenia related to persistent or progressive BM metastasis. Although known bone metastasis is not a contraindication to PRRT, thrombocytopenia may be a manifestation of tumor progression and should be considered when making decisions about continuation of therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004130","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T03:01:16Z","timestamp":1647831676000},"page":"409-413","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy"],"prefix":"10.1097","volume":"47","author":[{"given":"Junid A.","family":"Naveed Ahmad","sequence":"first","affiliation":[{"name":"Cancer Institute, Virginia Mason Medical Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett B.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Ruhoy","sequence":"additional","affiliation":[{"name":"Anatomic and Clinical Pathology, Virginia Mason Medical Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen F.","family":"Kennecke","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute Franz Clinic, Portland, OR."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce S.","family":"Lin","sequence":"additional","affiliation":[{"name":"Cancer Institute, Virginia Mason Medical Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13256-015-0514-y","article-title":"Large cell neuroendocrine carcinoma of the lung presenting as pseudoachalasia: a case report","volume":"9","year":"2015","journal-title":"J Med Case Reports"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","year":"2008","journal-title":"Lancet Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","year":"2017","journal-title":"JAMA Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history","volume":"733","year":"1994","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 2","key":"bib8-20250621","first-page":"S23","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","year":"1999","journal-title":"Ann Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study","volume":"38","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2016.01.009","article-title":"Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: a multi-institutional registry study with prospective follow-up","volume":"58","year":"2016","journal-title":"Eur J Cancer"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for Midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00259-014-2735-5","article-title":"177Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib16-20250621","first-page":"74","article-title":"Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis","volume":"7","year":"2017","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/MPA.0000000000000113","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience","volume":"43","year":"2014","journal-title":"Pancreas"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","article-title":"Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib19-20250621","first-page":"593","article-title":"Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"27","year":"2012","journal-title":"Cancer Biother Radiopharm"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4103\/1450-1147.165353","article-title":"Metastatic neuroendocrine tumor with extensive bone marrow involvement at diagnosis: evaluation of response and hematological toxicity profile of PRRT with (177)Lu-DOTATATE","volume":"15","year":"2016","journal-title":"World J Nucl Med"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"L17","DOI":"10.1530\/ERC-15-0543","article-title":"High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy","volume":"23","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1159\/000441604","article-title":"Is there an additional value of using somatostatin receptor subtype 2a immunohistochemistry compared to somatostatin receptor scintigraphy uptake in predicting gastroenteropancreatic neuroendocrine tumor response","volume":"103","year":"2016","journal-title":"Neuroendocrinology"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.3390\/cancers13092035","article-title":"Evaluation of SSTR2 expression in SI-NETs and relation to overall survival after PRRT","volume":"13","year":"2021","journal-title":"Cancers (Basel)"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00259-016-3486-2","article-title":"The prognostic and predictive value of SSTR-2 immunohistochemistry and SSTR-2 targeted imaging in neuroendocrine tumors","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1677\/ERC-09-0078","article-title":"Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors","volume":"17","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1677\/ERC-08-0301","article-title":"Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma","volume":"16","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"bib27-20250621","first-page":"223","article-title":"Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors","volume":"47","year":"2006","journal-title":"J Nucl Med"},{"key":"bib28-20250621","first-page":"1602","article-title":"Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy","volume":"40","year":"1999","journal-title":"J Nucl Med"},{"key":"bib29-20250621","first-page":"184","article-title":"Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism","volume":"44","year":"2003","journal-title":"J Nucl Med"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","article-title":"Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization","volume":"12","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/ERC-08-0017","article-title":"Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours","volume":"15","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"bib32-20250621","first-page":"437","article-title":"Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis","volume":"3","year":"2013","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes","volume":"95","year":"2012","journal-title":"Neuroendocrinology"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2967\/jnumed.111.090373","article-title":"Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3413\/Nukmed-0614-13-08","article-title":"Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement","volume":"53","year":"2014","journal-title":"Nuklearmedizin"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"635","DOI":"10.20452\/pamw.2505","article-title":"Unexpected cause of anemia: metastasis of neuroendocrine tumor to the bone marrow","volume":"124","year":"2014","journal-title":"Pol Arch Med Wewn"}],"updated-by":[{"DOI":"10.1097\/rlu.0000000000004324","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000}}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T16:03:09Z","timestamp":1750521789000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004130","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,18]]}}}